Merck & Co Inc (MRK)

MRK on New York Consolidated

49.16USD
9 Feb 2016
Change (% chg)

$0.33 (+0.68%)
Prev Close
$48.83
Open
$48.69
Day's High
$49.57
Day's Low
$48.40
Volume
10,649,089
Avg. Vol
11,810,747
52-wk High
$61.70
52-wk Low
$45.69

MRK

Chart for MRK

About

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine... (more)

Overall

Beta: 0.69
Market Cap(Mil.): $136,408.70
Shares Outstanding(Mil.): 2,793.54
Dividend: 0.46
Yield (%): 3.77

Financials

  MRK Industry Sector
P/E (TTM): 31.23 31.78 38.48
EPS (TTM): 1.56 -- --
ROI: -- 14.97 14.34
ROE: -- 15.61 15.17
Search Stocks

Merck gives cautious 2016 outlook as sales of top medicines lag

Merck & Co Inc on Wednesday issued a cautious 2016 outlook and reported disappointing fourth-quarter sales of its Januvia diabetes treatment and its Remicade arthritis drug, sending its shares down nearly 3 percent.

03 Feb 2016

UPDATE 3-Merck gives cautious 2016 outlook as sales of top medicines lag

Feb 3 Merck & Co Inc on Wednesday issued a cautious 2016 outlook and reported disappointing fourth-quarter sales of its Januvia diabetes treatment and its Remicade arthritis drug, sending its shares down nearly 3 percent.

03 Feb 2016

BRIEF-Merck sees accelerating declines for Remicade, due to biosimilars

* Says it expects global Januvia/Janumet sales to rise in 2016, when excluding negative impact of strong dollar

03 Feb 2016

Merck revenue falls as dollar strengthens

Feb 3 Merck & Co Inc reported a 2.5 percent fall in quarterly revenue, hurt by a strong dollar and declining sales of its Remicade arthritis treatment.

03 Feb 2016

UPDATE 2-Gilead hepatitis C drug sales beat estimates, but growth stalls

LOS ANGELES, Feb 2 Gilead Sciences Inc's hepatitis C drug sales edged past Wall Street estimates in the fourth quarter, helped by strong sales in Japan, but U.S. results were weaker than expected.

02 Feb 2016

Payers see price leverage with entry of Merck hepatitis C drug

Jan 29 U.S. pharmacy benefit managers expect the launch of Merck & Co Inc's new hepatitis C pill to improve their leverage in price negotiations with drugmakers.

29 Jan 2016

FDA approves Merck's new hepatitis C pill

U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors.

28 Jan 2016

UPDATE 1-U.S. FDA approves Merck's new hepatitis C pill

Jan 28 U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors.

28 Jan 2016

U.S. FDA approves Merck's new hepatitis C pill

Jan 28 U.S. regulators on Thursday approved a new once-daily treatment for the liver-destroying hepatitis C virus made by Merck & Co Inc.

28 Jan 2016

Bristol-Myers set to lead earnings parade in 2016, beyond

Bristol-Myers Squibb Co on Thursday positioned itself as a potential earnings pacesetter in 2016, with a forecast of up to 19 percent growth that eclipses profit gains expected by most other large drugmakers.

28 Jan 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks